Binders Excipients Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Growth of Generic and Biosimilar Oral Solid Dose Manufacturing

Generic oral solid dosage forms remain the primary volume driver for binders, with the patent expiry cycle continuing to support demand. The FDA’s generic drug program is expected to process more than 35,000 cumulative ANDA approvals through 2025. The growing number of biosimilar approvals also supports future formulation activity, although binder requirements vary by dosage form. Large-scale manufacturing programs favor grades that deliver stable granules and consistent compression performance. The binders excipients market benefits as generic manufacturers expand tablet and capsule production across multiple therapeutic areas. Binder qualification is increasingly shifting to CDMOs, which manage development and manufacturing for multiple customers, rather than remaining solely at originator sites. Suppliers that pre-qualify grades for standard generic platforms and maintain current regulatory files across multiple jurisdictions are better positioned to secure repeat orders.

Demand for Multifunctional and Co-processed Excipients

Co-processed excipients provide binding, filling, and disintegration functions within direct-compression workflows. A 2025 study found that co-processed excipients improved flowability, compressibility, and disintegration performance compared with physical blends of their individual components. These attributes are increasingly important for tablet manufacturers operating high-speed presses and seeking to streamline formulation processes. The existing pharmacopoeial status of the underlying materials can also simplify the development pathway compared with introducing a new chemical entity. Evonik is expected to receive a Market Impact Award at CPHI China 2026 for its EUDRAGIT polymer platform, underscoring the commercial value of functional polymer systems. The binders excipients market is moving toward suppliers that combine co-processing capabilities with formulation support. Commodity suppliers offering only starch or PVP grades face increasing challenges as customers seek integrated performance solutions.

Expansion of Pharmaceutical and Nutraceutical Production in the Asia-Pacific

Pharmaceutical production across Asia-Pacific is driving demand for binders with consistent specifications and pharmaceutical-grade manufacturing controls. India’s production-linked incentive program for APIs and bulk drugs supports broader pharmaceutical capacity expansion. New granulation and tablet manufacturing facilities require GMP-grade inputs that comply with Central Drugs Standard Control Organisation requirements. Sigachi reported a 29.57% increase in microcrystalline cellulose production in FY2025 and plans to commission a croscarmellose sodium facility in Dahej by late 2026. The company targets total microcrystalline cellulose capacity of 25,000 MTPA. Nutraceutical tablets and softgels further increase demand for materials that provide binding and processing support. Ashland plans to begin construction of its first South Asian tablet-coatings facility in Ambernath in June 2026, citing India’s base of more than 3,000 pharmaceutical manufacturers and access to the Pune and Hyderabad formulation clusters.

Continuous Manufacturing and High-Shear Granulation Adoption

Continuous manufacturing is changing the binder attributes that pharmaceutical teams evaluate during process development. The FDA is expected to approve 22 drug products manufactured through continuous manufacturing processes by mid-2026, compared with 6 products in 2022. The agency’s GDUFA IV framework introduces meeting types for complex generic submissions that may involve new process parameters. Continuous wet granulation research published in 2025 demonstrated a process that uses crystallization-water-releasing excipients instead of external granulation liquid. The research reported granule tensile strength above 1.5 MPa and scale-up from 0.5 kg/h to 10 kg/h without formulation changes. DFE Pharma plans to launch a continuous manufacturing platform with Gericke in Hyderabad in February 2026, enabling customers to evaluate continuous-manufacturing-ready excipients before process lock. The binders excipients market favors suppliers with dedicated testing capabilities, as binder selection can occur during process design rather than after development.

Complex and Regionally Variable Excipient Regulation

The absence of a harmonized global regulatory framework for excipients creates ongoing compliance challenges for suppliers and formulators. In the United States, excipients are reviewed as part of the finished drug application, with Type IV Drug Master Files serving as a standard documentation pathway. In the European Union, the European Medicines Agency’s (EMA) draft guideline defines excipient requirements for marketing authorization dossiers. China follows a national standards system that does not fully align with the United States Pharmacopeia–National Formulary (USP–NF) and European Pharmacopeia monographs. The EMA is expected to update its excipient labeling annex guidance in 2025, while the World Health Organization (WHO) issued good manufacturing practice (GMP) guidance for excipient manufacturers in 2024^{[1]World Health Organization, “Good Manufacturing Practices for Excipients Used in Pharmaceutical Products,” World Health Organization, who.int}. These differing regulatory requirements increase compliance costs for participants in the binders and excipients market, particularly due to the need for multi-compendial compliance and variation filings. The burden is more pronounced for smaller regional suppliers, while established suppliers benefit from their ability to support global customers and retain key accounts.

High Qualification and Change-Control Costs

Once a binder is included in regulatory submissions and used in approved medicines, any change requires a formal change-control process. Changes to manufacturing sites, synthesis routes, raw material sources, or grade specifications can trigger a Prior Approval Supplement or a Type II variation. The IPEC Federation’s Version 3 guide, expected in 2026, is anticipated to state that significant Level 2 changes require notification to users and, in some cases, regulatory authorities. These processes require coordination among pharmaceutical manufacturers, excipient suppliers, quality teams, and regulatory authorities. When products are registered across multiple regions, resolution can take 6 to 18 months. Consequently, manufacturers often continue working with qualified suppliers, even when alternative materials offer lower prices or different performance characteristics. This dynamic strengthens the position of incumbent suppliers but can delay the adoption of alternative binder technologies among mid-sized generic drug manufacturers.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Binders Excipients Market Segment Analysis

Natural binders are expected to account for 57.65% of the binders excipients market share in 2025. Their leading position is supported by established pharmacopoeial status, broad regulatory acceptance, and lower qualification requirements than many synthetic alternatives. Microcrystalline cellulose, hydroxypropyl methylcellulose, starch, and guar gum are expected to account for a significant share of natural binder use in tablet manufacturing. Gelatin will remain relevant for selected tablet formats and modified-release capsule fills. Semi-synthetic materials offer a balance between familiar source materials and more controlled functional performance.

Synthetic binders are projected to be the fastest-growing source category, with a forecast CAGR of 6.5% from 2026 to 2031. PVP and copovidone offer tighter viscosity control, greater batch consistency, and compatibility with twin-screw granulation. A 2025 study is expected to demonstrate that viscosity and surface tension influence granule growth and tablet tensile strength during high-shear wet granulation. The EU restriction on synthetic polymeric microplastics will introduce reporting obligations for materials within its scope from May 2027. As a result, the source mix within the binders excipients market will be influenced by both processing performance and evolving compliance requirements.

Tablets are expected to account for 37.86% of the binders excipients market size in 2025. Oral solid dosage forms remain widely used because they support patient adherence, scalable manufacturing, and lower production costs than many injectable and liquid formats. Binders facilitate granule formation and maintain tablet integrity during compression. Capsules use binders in wet-filled and granule-filled formats, while modified-release matrices require controlled hydrophilic swelling behavior. Colorcon’s 2025 partnership with ASHA Cellulose will cover ethyl cellulose polymers for binding, film forming, taste masking, and sustained release across several regions.

Solution-based formulations are forecast to grow at a CAGR of 6.8% from 2026 to 2031. Pediatric and geriatric programs are driving demand for liquid and semi-solid oral products, as these populations may have difficulty swallowing tablets. In these formulations, binders provide viscosity and stabilize suspended ingredients. FDA and EMA pediatric frameworks support the development of age-appropriate formulations. ICH Q8 documentation can encourage solution manufacturers to retain previously qualified suppliers, even when they face pricing pressure.

Pharmaceutical companies are expected to account for 46.87% of the binders excipients market size in 2025. Their in-house tablet and capsule operations generate consistent demand across innovator and generic drug portfolios. Nutraceutical companies use binders in vitamin, mineral, tablet, and softgel products. Biotechnology companies and research laboratories represent smaller, project-based buyers, including those involved in oral peptide and biologic delivery programs. Ashland will launch Permexa sodium caprate in August 2026 for oral peptide and biologic drug delivery, including GLP-1 agonist formulations.

CDMOs are projected to record the highest end-user CAGR, at 7.9% through 2031. They manage development and manufacturing activities for generic, biosimilar, and specialty drug programs, shifting binder qualification closer to multi-client production sites. Long-term supply agreements may include quality audits and detailed documentation requirements. Evonik will announce a USD 100 million investment in July 2026 to modernize its Lafayette, Indiana, drug-substance CDMO facility over five years. Suppliers that demonstrate validated performance in CDMO development programs are more likely to secure specifications before formulations are finalized.

Geography Analysis

North America Binders Excipients Market

North America is expected to account for 43.65% of the binders excipients market size in 2025. Large generic drug operations, FDA-centered regulation, and GMP manufacturing facilities underpin the region’s position in the binders and excipients market. GDUFA IV will take effect in 2028 and introduce pre-submission meeting types for complex generic drug applicants. The National Supply Chain Resilience Act will require domestic or allied-nation sourcing for 50% of APIs used in Medicare and Medicaid drugs by 2030. BASF will open a GMP Solution Center in Wyandotte, Michigan, in June 2025, while Canada and Mexico will contribute additional demand^{[2]BASF SE, “BASF Strengthens Its Commitment to the Biopharma and Pharmaceutical Ingredients Industries,” BASF Media, basf.com}.

Europe, South America and APAC Binders Excipients Market

Europe will maintain a significant position in the binders excipients market, led by Germany, France, and the United Kingdom. These countries have established pharmaceutical manufacturers and generic drug producers that use cellulose, starch, and polymer binders. Germany benefits from local supply networks that include Evonik, BASF, and MEGGLE. Evonik and Higuchi will open the Open Pharma Lab in Yokohama in April 2026, extending European technical support into Asia. European suppliers will manage compliance costs associated with REACH and EMA labeling guidance, while Brazil will lead demand in South America.

APAC and MEA Binders Excipients Market

Asia-Pacific is forecast to grow at a CAGR of 5.7% from 2026 to 2031, representing the fastest growth rate in the binders excipients market. India supplies more than 20% of global generic drug volumes and requires reliable GMP-grade binders. India’s QR code requirement, scheduled for March 2026, will formalize excipient identity documentation, while Chinese producers are increasing the supply of locally certified binders. The Middle East and Africa will remain smaller but active markets as Saudi Arabia, the UAE, and South Africa expand pharmaceutical manufacturing capacity.